易明医药(002826) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue was CNY 161,865,262.97, a decrease of 21.45% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 9,807,201.16, an increase of 5.78% year-on-year[4] - Net profit excluding non-recurring items was CNY -1,669,312.88, a decline of 120.67% compared to the previous year[4] - Total operating revenue for Q3 2023 was CNY 538,300,734.55, a decrease of 9.0% compared to CNY 591,767,346.30 in the same period last year[28] - Net profit for Q3 2023 reached CNY 24,399,796.33, an increase of 13.5% compared to CNY 21,481,158.04 in Q3 2022[29] - The company reported a total comprehensive income of CNY 25,440,081.08 for Q3 2023, compared to CNY 21,578,036.05 in Q3 2022[29] Assets and Liabilities - Total assets at the end of Q3 2023 were CNY 983,956,526.95, down 3.36% from the end of the previous year[4] - Total assets as of the end of Q3 2023 were CNY 983,956,526.95, compared to CNY 1,018,204,645.88 at the end of Q3 2022[26] - Total liabilities decreased to CNY 224,970,850.51 from CNY 268,208,437.62 year-over-year, indicating improved financial stability[26] - The company's equity attributable to shareholders increased to CNY 753,771,536.18 from CNY 745,293,911.40 in the previous year[26] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 78,105,720.88, a decrease of 15.00%[4] - The net cash flow from operating activities for the first nine months of 2023 was ¥78,105,720.88, a decrease of 15.00% compared to ¥91,887,610.24 in the same period of 2022[11] - Operating cash flow for the period was CNY 78,105,720.88, a decrease of 14.9% compared to CNY 91,887,610.24 in the previous period[30] - Total cash inflow from operating activities was CNY 694,947,408.36, down from CNY 721,398,791.01, reflecting a decline of 3.5%[30] - Cash outflow from operating activities totaled CNY 616,841,687.48, compared to CNY 629,511,180.77, indicating a decrease of 2.0%[30] - Net cash flow from financing activities was CNY -60,154,351.92, a decline from CNY 28,096,267.97 in the previous period[31] Investments and Expenses - The company made a long-term equity investment of CNY 42,455,625.95, acquiring a 20% stake in Pier 88 Health Limited[9] - Research and development expenses increased by 249.32% to ¥11,672,853.41, driven by ongoing research on listed products and the development of L-lysine raw materials and formulations[10] - Management expenses increased by 30.26% to ¥40,294,917.48, attributed to higher travel and consulting service costs as business activities resumed[10] - The company reported a significant increase in special reserves, which reached ¥2,678,125.11, up 4260.84% due to safety production fee provisions[10] - The company experienced a credit impairment loss of ¥2,261,975.04, an increase of 437.97%, due to improved management of receivables[10] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,780[13] - The largest shareholder, Gao Fan, holds 25.59% of the shares, with 10,372,800 shares pledged[13] Credit and Financing - The company applied for a credit limit of RMB 100 million from CITIC Bank, with procedures completed, and is awaiting further operational plans for withdrawal[18] - The company has applied for a credit limit of RMB 50 million from Chengdu Bank and is in the process of providing guarantees for its subsidiaries[18] Cash and Equivalents - The company reported a decrease in cash and cash equivalents from RMB 321.28 million at the beginning of the year to RMB 227.59 million as of September 30, 2023, a decline of approximately 29.2%[24] - The ending cash and cash equivalents balance was CNY 182,588,913.27, down from CNY 200,638,206.96, reflecting a decrease of 9.0%[31]